Jianhua Yu, PhD

Specific Targeting of the Leukemia-Associated Antigen FLT3 Using Chimeric Antigen Receptor (CAR)-Engineered NK Cells for Treatment of Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutations

Leukemia patients with some mutations routinely relapse and have worse survival. We will engineer immune cells with the ability to specifically bind tumor cells in patients who are resistant to other treatments. This will enable immune cells to specifically and efficiently spot and kill tumor cells without harming normal cells.